Author:
Yapp Donald T.,Wong May Q.,Kyle Alastair H.,Valdez Shannon M.,Tso Jenny,Yung Andrew,Kozlowski Piotr,Owen David A.,Buczkowski Andrzej K.,Chung Stephen W.,Scudamore Charles H.,Minchinton Andrew I.,Ng Sylvia S. W.
Funder
Canadian Institutes of Health Research
Canadian Cancer Society Research Institute (CA)
Canadian Institutes of Health Research (CA)
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Biochemistry,Physiology
Reference58 articles.
1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300. doi: 10.3322/caac.20073
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886
4. Andre N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC (2008) Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 30(7):1336–1340
5. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献